Drug Profile
Research programme: sodium hydrogen exchanger-3 inhibitors - Ardelyx
Alternative Names: NHE3 inhibitors - Ardelyx; RDX-011; RDX011-1Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Ardelyx
- Class Heart failure therapies; Small molecules
- Mechanism of Action Sodium-hydrogen exchanger 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders; Heart failure; Kidney disorders
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 28 Jun 2020 No recent reports of development identified for research development in Heart-failure in USA
- 28 Jun 2020 No recent reports of development identified for research development in Kidney-disorders in USA